Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
X-Chem
Waltham, Massachusetts, United Statesx-chemrx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
X-Chem has enabled the identification of functional hits in over 80% of projects, with nearly 100 licensed discovery programs and more than 1000 validated hit compounds delivered to partners. The company’s DEL and AI platforms have been successfully applied across at least 30 target classes, supporting both pharma and biotech clients in early-stage drug discovery
- Therapeutic areas
- Other
- Modalities
- Small moleculeDNA-encoded library (DEL) compounds
- Industry
- Drug Discovery Services
02
Partnerships
Beyond the preview
Go deeper on X-Chem.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on X-Chem.